Dr Geoffrey Vernon: Chairman Geoffrey is a member of the Royal Pharmaceutical Society and a Fellow of the Institute of Directors. He has extensive corporate governance experience in private and public companies and was accredited in 1999 as the first Director in the UK with the professional qualification of Chartered Director. Over the last fifteen years he has established credibility with European and US investment bankers, analysts and financial institutions. He has worked in industry, public and private companies, venture capital and has exposure to fund management.

Dr Nigel Pitchford: Director Nigel joined Imperial Innovations as Managing Director of Healthcare in January 2012, and became Chief Investment Officer of Imperial Innovations Group in October 2013. He was previously a Partner at DFJ Esprit, and prior to that spent 12 years at 3i, becoming a Partner in 2006, and ultimately leading the venture team's healthcare activities across Europe and the US. He has also served on the boards of EUSA Pharma and HBI. Nigel is currently a non-executive director on the boards of Oxford Immunotec, Polytherics and E3Bio.

Alastair Stewart: Director Alastair is an Investment Manager at Oxford Capital Partners, which he joined in 2006. As a member of the investment team he is responsible for making investments in the software, sustainability and healthcare sectors. He also sits on the Advisory Panel of the DECC Energy Entrepreneurs Fund and holds a degree in Engineering Science from Magdalen College, Oxford, where he focused on new developments in 3D visualisation of blood flow in catheterised brain aneurysms. He previously worked at O2 (Telefónica).

Alan O’Connell: Director Alan is a Partner at Seroba Kernel Life Sciences. Prior to joining Seroba Kernel, Alan worked in a variety of product development and business development roles at Elan Corporation (Dublin), American Biogenetic Sciences, Inc. (New York), and the Medicines Control Agency (London). His previous venture capital experience was gained at Estée Lauder Investments (New York) and he still sits on the Lauder Scientific Advisory Board. In addition to Veryan, Alan sits on the boards of Biosensia (Irl), Crescent Diagnostics (UK) and Alimentary Health (Irl).

Todd Pope: Non-Executive Director Todd has spent more than 20 years working in leadership positions within the medical device industry. He is currently President and CEO of minimally invasive surgery specialists TransEnterix. Prior to joining TransEnterix, Todd served as worldwide president of Cordis, a specialist medical device division of Johnson & Johnson. He previously held a number of leadership positions within Johnson & Johnson and Boston Scientific.

Jeffrey B. Jump: Non-Executive Director Jeff has nearly 30 years’ experience of the medical device industry. He is currently President of interventional cardiology specialists Biosensors, a company with which he has held a succession of senior management roles since 2003. He is also a non-Executive Director of several start-up medical device companies. Over the course of his career Jeff has held senior management roles with Xitact Medical Simulation, Embol-X, Alliance Medical Technologies, Cardio Thoracic Systems, Haemonetics S.A. and Pfizer Hospital Products Group.